

**MEDIA RELEASE
FOR IMMEDIATE RELEASE**

ACROMETA clinches 2 contracts worth \$6 million

SINGAPORE, 08 July 2022 – ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider Group in the field of controlled environments serving mainly the healthcare, biomedical, pharmaceutical, research and academia sectors, today announces that it has secured two contracts totalling approximately S\$6 million.

The first project is a follow-up expansion project from a customer in the biotechnology sector, where we first built its laboratory facility in Kallang Way back in May 2021. The Group greatly appreciates with the continued collaboration.

The second project involves the construction of joint laboratory facility for two companies similarly in the biotechnology space, specialising in advance immunotherapy.

The contracts are expected to contribute positively to the earnings per share and net tangible assets per share of the Group for the current financial year ending 30 September 2022.

To the best of the Directors’ knowledge, none of the Directors and controlling shareholders of the Company have any interests, direct or indirect, in these contracts, other than through their respective shareholdings in the Company.

– End –

About ACROMETA Group Limited (SGX Stock Code: 1CH1)

ACROMETA (Previously known as ACROMECA Limited) is an established specialist engineering services provider with more than 20 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMETA's business is divided into two main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure.

The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.

The company has been listed on the Catalist board of the Singapore Exchange since 2016.

For more information, please visit www.acrometa.com.

Media and Analysts Contact:

ACROMETA Group Limited

Mr Jerry Tan

Chief Financial Officer

Tel: +65 6415 0574

Email: jerry.tan@acromec.com

Waterbrooks Consultants Pte Ltd

Mr Wayne Koo

Tel: +65 6958 8008 / +65 9338 8166

Email: wayne.koo@waterbrooks.com.sg

Email: query@waterbrooks.com.sg

This media release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Joseph Au, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.